コーパス検索結果 (right1)
通し番号をクリックするとPubMedの該当ページを表示します
1 nome-and expressed HB surface antigen at levels relevant to patients.
2 with hypoxia and hemodynamic instability in critically ill patients.
3 detected in the BM plasma samples from MM compared to MGUS patients.
4 95% CI: 1.6, 2.3; P = .02); RB1 mutation (seen in 19 of 103 patients, 18.4%) was associated with peritoneal carcinomatosi
8 ctive for the treatment of anemia in chronic kidney disease patients and may also be beneficial for the treatment of dise
9 ent of rheumatoid arthritis (RA), a substantial minority of patients are exposed to multiple DMARDs without necessarily b
10 eism in nursing is particularly significant because it puts patients at risk by reducing the capacity of nurses to provid
13 the end of dasatinib induction therapy (day 85), 29% of the patients had a molecular response, and this percentage increa
15 ge acquisition method for capturing RBC images from the SCD patients in normoxia and hypoxia conditions.
16 llected between 20 February and 15 March 2020 from infected patients in Washington state in the United States.
18 review was to investigate treatment outcomes among PWID and patients on OST in comparison to control cohorts.
19 Outcomes were assessed according to patients' receipt of initial assessments by a lung cancer nur
24 duction in neuroinflammation by using samples from post-FMT patients to colonize GF mice shows a direct effect of fecal m
25 essive and usually noninvasive tumors that recur and commit patients to long-term invasive surveillance, to aggressive an
27 es from gastrointestinal and blood cultures of 24 pediatric patients undergoing chemotherapy or hematopoietic stem cell t
28 MARDs without necessarily benefitting from them; a group of patients variously designated as having 'difficult to treat',
36 ents who had GHPs showing neoplastic transformation with 39 patients who had non-neoplastic GHPs.
38 to 60% after two cycles of blinatumomab; the percentage of patients with a molecular response increased further after ad
39 A2 serotype (HLA-A2) that has been observed in about 35% of patients with acute myeloid leukaemia (AML).
40 remains underused in clinical practice, particularly among patients with alcohol-associated or NASH-related cirrhosis an
41 erence in the risk of cardiovascular death was observed for patients with and without postoperative AF (incidence rate, 4
42 score, 0 [interquartile range {IQR} 0-1] vs 1 [IQR 0-2] in patients with any positive BDG test; P = .039).
48 The study was designed to detect improvement in outcomes of patients with stage II to IV DAWT compared with historical co
49 as single-agent therapy with a manageable safety profile in patients with treatment-naive, or relapse or refractory Walde